<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Respir Res</journal-id><journal-title>Respiratory Research</journal-title><issn pub-type="ppub">1465-9921</issn><issn pub-type="epub">1465-993X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17341317</article-id><article-id pub-id-type="pmc">1821019</article-id><article-id pub-id-type="publisher-id">1465-9921-8-19</article-id><article-id pub-id-type="doi">10.1186/1465-9921-8-19</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Haney</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>sas_haney@yahoo.co.uk</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Hancox</surname><given-names>Robert J</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>bob.hancox@otago.ac.nz</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Respiratory Medicine, Sunderland Royal Hospital, Sunderland, UK</aff><aff id="I2"><label>2</label>Department Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand</aff><aff id="I3"><label>3</label>Dunedin Multidisciplinary Health and Development Research Unit, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand</aff><pub-date pub-type="ppub"><year>2007</year></pub-date><pub-date pub-type="epub"><day>6</day><month>3</month><year>2007</year></pub-date><volume>8</volume><issue>1</issue><fpage>19</fpage><lpage>19</lpage><ext-link ext-link-type="uri" xlink:href="http://respiratory-research.com/content/8/1/19"></ext-link><history><date date-type="received"><day>29</day><month>6</month><year>2006</year></date><date date-type="accepted"><day>6</day><month>3</month><year>2007</year></date></history><permissions><copyright-statement>Copyright © 2007 Haney and Hancox; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Haney and Hancox; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3005" xml_f="3015" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3026" xml_f="3451" txt_i="22" txt_f="447">Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is impaired. We assessed the effect of long-acting beta-agonist treatment on the response to 5 mg nebulised salbutamol and to ipratropium bromide.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="3492" xml_f="3499" txt_i="449" txt_f="456">Methods</offsets></title><p><offsets xml_i="3510" xml_f="3630" txt_i="457" txt_f="577">Two double-blind, placebo-controlled, crossover studies of inhaled formoterol 12 μg twice daily in patients with asthma.</offsets></p><p><italic><offsets xml_i="3645" xml_f="3665" txt_i="578" txt_f="598">High-dose salbutamol</offsets></italic><offsets xml_i="3674" xml_f="3812" txt_i="598" txt_f="736">: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled methacholine to produce a 20% fall in FEV</offsets><sub><offsets xml_i="3817" xml_f="3818" txt_i="736" txt_f="737">1</offsets></sub><offsets xml_i="3824" xml_f="3889" txt_i="737" txt_f="802">. Salbutamol 5 mg was then administered via nebuliser and the FEV</offsets><sub><offsets xml_i="3894" xml_f="3896" txt_i="802" txt_f="804">1 </offsets></sub><offsets xml_i="3902" xml_f="3932" txt_i="804" txt_f="834">was monitored for 20 minutes. </offsets><italic><offsets xml_i="3940" xml_f="3951" txt_i="834" txt_f="845">Ipratropium</offsets></italic><offsets xml_i="3960" xml_f="4097" txt_i="845" txt_f="982">: 36 hours after the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled 4.5% saline to produce a 20% fall in FEV</offsets><sub><offsets xml_i="4102" xml_f="4103" txt_i="982" txt_f="983">1</offsets></sub><offsets xml_i="4109" xml_f="4186" txt_i="983" txt_f="1060">. Salbutamol 200 μg or ipratropium bromide 40 μg was then inhaled and the FEV</offsets><sub><offsets xml_i="4191" xml_f="4193" txt_i="1060" txt_f="1062">1 </offsets></sub><offsets xml_i="4199" xml_f="4431" txt_i="1062" txt_f="1294">was monitored for 30 minutes. Four study arms compared the response to each bronchodilator after formoterol and placebo. Analyses compared the area under the bronchodilator response curves, adjusting for changes in pre-challenge FEV</offsets><sub><offsets xml_i="4436" xml_f="4437" txt_i="1294" txt_f="1295">1</offsets></sub><offsets xml_i="4443" xml_f="4480" txt_i="1295" txt_f="1332">, dose of provocational agent and FEV</offsets><sub><offsets xml_i="4485" xml_f="4487" txt_i="1332" txt_f="1334">1 </offsets></sub><offsets xml_i="4493" xml_f="4529" txt_i="1334" txt_f="1370">fall during the challenge procedure.</offsets></p></sec><sec><title><offsets xml_i="4551" xml_f="4558" txt_i="1372" txt_f="1379">Results</offsets></title><p><offsets xml_i="4569" xml_f="4745" txt_i="1380" txt_f="1556">The response to nebulised salbutamol was 15% lower after formoterol therapy compared to placebo (95% confidence 5 to 25%, p = 0.008). The response to ipratropium was unchanged.</offsets></p></sec><sec><title><offsets xml_i="4767" xml_f="4777" txt_i="1558" txt_f="1568">Conclusion</offsets></title><p><offsets xml_i="4788" xml_f="5021" txt_i="1569" txt_f="1802">Long-acting beta-agonist treatment induces tolerance to the bronchodilator effect of beta-agonists, which is not overcome by higher dose nebulised salbutamol. However, the bronchodilator response to ipratropium bromide is unaffected.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="5083" xml_f="5093" txt_i="1811" txt_f="1821">Background</offsets></title><p><offsets xml_i="5104" xml_f="5226" txt_i="1822" txt_f="1944">Patients with asthma who are poorly controlled on inhaled corticosteroids are often prescribed long-acting beta-agonists [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5257" xml_f="5258" txt_i="1944" txt_f="1945">1</offsets></xref><offsets xml_i="5265" xml_f="5266" txt_i="1945" txt_f="1946">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5297" xml_f="5298" txt_i="1946" txt_f="1947">2</offsets></xref><offsets xml_i="5305" xml_f="5701" txt_i="1947" txt_f="2343">]. However, most asthmatics continue to need short acting beta-agonists for relief of breakthrough symptoms and for treatment during asthma exacerbations. Despite accumulating evidence that tolerance develops to the bronchodilator effects of beta-agonists, the effect of regular long-acting beta-agonists on the response to treatment of exacerbations is rarely considered in treatment guidelines.</offsets></p><p><offsets xml_i="5708" xml_f="5735" txt_i="2344" txt_f="2371">Tolerance to the systemic [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5766" xml_f="5767" txt_i="2371" txt_f="2372">3</offsets></xref><offsets xml_i="5774" xml_f="5799" txt_i="2372" txt_f="2397">] and bronchoprotective [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5830" xml_f="5831" txt_i="2397" txt_f="2398">4</offsets></xref><offsets xml_i="5838" xml_f="6178" txt_i="2398" txt_f="2738">] effects of beta-agonists is known to occur during regular beta-agonist use. It was previously thought that tolerance to bronchodilation did not occur. However, recent studies have shown that tolerance to bronchodilation is easily demonstrated when tested from a bronchoconstricted state, such as after methacholine or exercise challenge [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6209" xml_f="6210" txt_i="2738" txt_f="2739">5</offsets></xref><offsets xml_i="6217" xml_f="6218" txt_i="2739" txt_f="2740">-</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="6250" xml_f="6252" txt_i="2740" txt_f="2742">13</offsets></xref><offsets xml_i="6259" xml_f="6531" txt_i="2742" txt_f="3014">]. Patients using regular long-acting beta-agonists may therefore be less responsive to further beta-agonist treatment during acute bronchoconstriction. This is potentially a serious problem for patients who are taking these drugs and experience an exacerbation of asthma.</offsets></p><p><offsets xml_i="6538" xml_f="6713" txt_i="3015" txt_f="3190">Studies of bronchodilator tolerance have demonstrated that regular beta-agonist treatment impairs the bronchodilator response to moderate doses of up to 400 μg of salbutamol [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6744" xml_f="6745" txt_i="3190" txt_f="3191">5</offsets></xref><offsets xml_i="6752" xml_f="6753" txt_i="3191" txt_f="3192">-</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="6785" xml_f="6787" txt_i="3192" txt_f="3194">12</offsets></xref><offsets xml_i="6794" xml_f="6953" txt_i="3194" txt_f="3353">]. It has been suggested that this tolerance can easily be overcome by administering higher doses of beta-agonists, but this has never been formally examined [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="6985" xml_f="6987" txt_i="3353" txt_f="3355">14</offsets></xref><offsets xml_i="6994" xml_f="7159" txt_i="3355" txt_f="3520">]. Treatment of asthma exacerbations in emergency departments usually includes higher doses of beta-agonists given via a nebuliser, typically up to 5 mg salbutamol [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7190" xml_f="7191" txt_i="3520" txt_f="3521">1</offsets></xref><offsets xml_i="7198" xml_f="7199" txt_i="3521" txt_f="3522">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7230" xml_f="7231" txt_i="3522" txt_f="3523">2</offsets></xref><offsets xml_i="7238" xml_f="7369" txt_i="3523" txt_f="3654">]. There have been no randomised controlled trials of the effects of regular long-acting beta-agonists on this emergency treatment.</offsets></p><p><offsets xml_i="7376" xml_f="7669" txt_i="3655" txt_f="3948">It is also unknown whether beta-agonist tolerance use affects the airway response to other bronchodilators. The anticholinergic bronchodilator ipratropium bromide is often added to emergency asthma treatment in severe bronchoconstriction and in those who respond poorly to beta-agonist alone [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7700" xml_f="7701" txt_i="3948" txt_f="3949">2</offsets></xref><offsets xml_i="7708" xml_f="7709" txt_i="3949" txt_f="3950">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="7741" xml_f="7743" txt_i="3950" txt_f="3952">15</offsets></xref><offsets xml_i="7750" xml_f="7927" txt_i="3952" txt_f="4129">]. It is likely that the bronchodilator response to ipratropium is not affected by prior long-acting beta-agonist treatment since it acts via a different receptor. However, beta</offsets><sub><offsets xml_i="7932" xml_f="7933" txt_i="4129" txt_f="4130">2</offsets></sub><offsets xml_i="7939" xml_f="8077" txt_i="4130" txt_f="4268">-receptors and muscarinic cholinergic receptors share some intracellular secondary messengers and their signalling pathways may interact [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="8109" xml_f="8111" txt_i="4268" txt_f="4270">16</offsets></xref><offsets xml_i="8118" xml_f="8119" txt_i="4270" txt_f="4271">,</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="8151" xml_f="8153" txt_i="4271" txt_f="4273">17</offsets></xref><offsets xml_i="8160" xml_f="8484" txt_i="4273" txt_f="4597">]. Hence it is plausible that bronchodilator responsiveness to ipratropium could be affected by beta-agonist tolerance. Moreover, it is possible that beta-agonists have a non-specific effect on airway smooth muscle tone thereby altering the response to other bronchodilators regardless of intracellular signalling pathways [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="8516" xml_f="8518" txt_i="4597" txt_f="4599">18</offsets></xref><offsets xml_i="8525" xml_f="8526" txt_i="4599" txt_f="4600">,</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="8558" xml_f="8560" txt_i="4600" txt_f="4602">19</offsets></xref><offsets xml_i="8567" xml_f="8569" txt_i="4602" txt_f="4604">].</offsets></p><p><offsets xml_i="8576" xml_f="8844" txt_i="4605" txt_f="4873">Given the role of high dose beta-agonist and ipratropium bromide in the management of asthma exacerbations, it is important to assess their effectiveness in the setting of long-acting beta-agonist treatment. We performed two studies to address the following questions:</offsets></p><p><offsets xml_i="8851" xml_f="8977" txt_i="4874" txt_f="5000">Study 1: Does high dose salbutamol overcome the bronchodilator tolerance associated with regular long-acting beta-agonist use?</offsets></p><p><offsets xml_i="8984" xml_f="9094" txt_i="5001" txt_f="5111">Study 2: Does beta-agonist bronchodilator tolerance affect the bronchodilator response to ipratropium bromide?</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="9135" xml_f="9142" txt_i="5113" txt_f="5120">Methods</offsets></title><sec><title><offsets xml_i="9162" xml_f="9170" txt_i="5121" txt_f="5129">Subjects</offsets></title><p><offsets xml_i="9181" xml_f="9271" txt_i="5130" txt_f="5220">Subjects had physician-diagnosed asthma with a provocative dose to cause a 20% fall in FEV</offsets><sub><offsets xml_i="9276" xml_f="9278" txt_i="5220" txt_f="5222">1 </offsets></sub><offsets xml_i="9284" xml_f="9287" txt_i="5222" txt_f="5225">(PD</offsets><sub><offsets xml_i="9292" xml_f="9294" txt_i="5225" txt_f="5227">20</offsets></sub><offsets xml_i="9300" xml_f="9699" txt_i="5227" txt_f="5626">) less than 1.5 mg of methacholine (study 1) or less than 30 ml saline (study 2) at screening (see below). Subjects were not using long-acting beta-agonists prior to the study and had not changed their asthma medications nor had a respiratory tract infection for 6 weeks prior to study entry. The studies were approved by the Waikato Ethics Committee. All subjects provided written informed consent.</offsets></p></sec><sec><title><offsets xml_i="9721" xml_f="9733" txt_i="5628" txt_f="5640">Study design</offsets></title><p><offsets xml_i="9744" xml_f="9964" txt_i="5641" txt_f="5861">Both studies were random-order, double-blind, cross-over studies comparing formoterol 12 μg twice daily with placebo. Randomisation was by computer-coded bottles of identical capsules for use with the Foradil Aeroliser (</offsets><italic><offsets xml_i="9972" xml_f="10003" txt_i="5861" txt_f="5892">Novartis, Auckland, New Zealand</offsets></italic><offsets xml_i="10012" xml_f="10121" txt_i="5892" txt_f="6001">). Additional beta-agonists were not allowed throughout the studies. Ipratropium was used for symptom relief.</offsets></p></sec><sec><title><offsets xml_i="10143" xml_f="10172" txt_i="6003" txt_f="6032">Study 1: High-dose salbutamol</offsets></title><p><offsets xml_i="10183" xml_f="10551" txt_i="6033" txt_f="6401">This was a crossover study with 2 arms. Subjects inhaled formoterol or placebo twice daily for 1 week. Thirty-six hours after the last dose, subjects underwent a methacholine challenge and salbutamol response as described below. Subjects then crossed to the other medication for a repeat sequence of 1 week of treatment, methacholine challenge and salbutamol response.</offsets></p><p><offsets xml_i="10558" xml_f="10627" txt_i="6402" txt_f="6471">Methacholine challenge was performed using a modified Yan technique [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="10659" xml_f="10661" txt_i="6471" txt_f="6473">20</offsets></xref><offsets xml_i="10668" xml_f="10742" txt_i="6473" txt_f="6547">]. Subjects inhaled doubling doses of nebulised methacholine until the FEV</offsets><sub><offsets xml_i="10747" xml_f="10749" txt_i="6547" txt_f="6549">1 </offsets></sub><offsets xml_i="10755" xml_f="10782" txt_i="6549" txt_f="6576">had fallen by ≥ 20%. The PD</offsets><sub><offsets xml_i="10787" xml_f="10790" txt_i="6576" txt_f="6579">20 </offsets></sub><offsets xml_i="10796" xml_f="11022" txt_i="6579" txt_f="6805">methacholine was calculated by linear interpolation of the last two doses. Immediately after completion of the methacholine challenge, subjects were given 5 mg salbutamol via a Sidestream nebuliser and System 22 aerosol mask (</offsets><italic><offsets xml_i="11030" xml_f="11055" txt_i="6805" txt_f="6830">Profile, Bognor Regis, UK</offsets></italic><offsets xml_i="11064" xml_f="11112" txt_i="6830" txt_f="6878">) powered by oxygen at a rate of 6 L/minute. FEV</offsets><sub><offsets xml_i="11117" xml_f="11119" txt_i="6878" txt_f="6880">1 </offsets></sub><offsets xml_i="11125" xml_f="11195" txt_i="6880" txt_f="6950">was measured at 5, 10, 15 and 20 minutes after starting the nebuliser.</offsets></p></sec><sec><title><offsets xml_i="11217" xml_f="11245" txt_i="6952" txt_f="6980">Study 2: Ipratropium bromide</offsets></title><p><offsets xml_i="11256" xml_f="11807" txt_i="6981" txt_f="7532">This was a crossover study with four arms. For each arm subjects inhaled formoterol 12 μg or placebo twice daily for 1 week. Thirty-six hours after the last dose, subjects underwent a hypertonic saline challenge and bronchodilator response as described below. Subjects then received the alternative medication and started the next arm of the study. Two study arms compared the bronchodilator response to salbutamol after formoterol and placebo treatment and the other two arms compared the response to ipratropium bromide after formoterol and placebo.</offsets></p><p><offsets xml_i="11814" xml_f="11917" txt_i="7533" txt_f="7636">Hypertonic saline challenge was performed according to the method of the European Respiratory Society [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="11949" xml_f="11951" txt_i="7636" txt_f="7638">21</offsets></xref><offsets xml_i="11958" xml_f="12003" txt_i="7638" txt_f="7683">]. Subjects inhaled 4.5% saline until the FEV</offsets><sub><offsets xml_i="12008" xml_f="12010" txt_i="7683" txt_f="7685">1 </offsets></sub><offsets xml_i="12016" xml_f="12037" txt_i="7685" txt_f="7706">fell by ≥ 20%. The PD</offsets><sub><offsets xml_i="12042" xml_f="12045" txt_i="7706" txt_f="7709">20 </offsets></sub><offsets xml_i="12051" xml_f="12257" txt_i="7709" txt_f="7915">saline was calculated by linear interpolation of the last two doses. Immediately after the challenge, 200 μg salbutamol or 40 μg ipratropium was given via a metered dose inhaler and large volume spacer. FEV</offsets><sub><offsets xml_i="12262" xml_f="12264" txt_i="7915" txt_f="7917">1 </offsets></sub><offsets xml_i="12270" xml_f="12337" txt_i="7917" txt_f="7984">was measured 5, 10, 15, 20 and 30 minutes after the bronchodilator.</offsets></p></sec><sec><title><offsets xml_i="12359" xml_f="12367" txt_i="7986" txt_f="7994">Analysis</offsets></title><p><offsets xml_i="12378" xml_f="12523" txt_i="7995" txt_f="8140">The main outcome measurement was the area under the salbutamol or ipratropium response curves (AUC), expressed as a percentage of the fall in FEV</offsets><sub><offsets xml_i="12528" xml_f="12530" txt_i="8140" txt_f="8142">1 </offsets></sub><offsets xml_i="12536" xml_f="12619" txt_i="8142" txt_f="8225">induced by challenge. Comparisons between treatments were adjusted for baseline FEV</offsets><sub><offsets xml_i="12624" xml_f="12626" txt_i="8225" txt_f="8227">1 </offsets></sub><offsets xml_i="12632" xml_f="12772" txt_i="8227" txt_f="8367">and dose of provocational agent given using analysis of covariance. A secondary outcome for each study was the final post-bronchodilator FEV</offsets><sub><offsets xml_i="12777" xml_f="12778" txt_i="8367" txt_f="8368">1</offsets></sub><offsets xml_i="12784" xml_f="12829" txt_i="8368" txt_f="8413">, which was also adjusted for the fall in FEV</offsets><sub><offsets xml_i="12834" xml_f="12836" txt_i="8413" txt_f="8415">1 </offsets></sub><offsets xml_i="12842" xml_f="12998" txt_i="8415" txt_f="8571">during challenge. Post hoc comparisons between placebo and formoterol treatments were were made using Tukey's exact method. Comparisons of pre-challenge FEV</offsets><sub><offsets xml_i="13003" xml_f="13005" txt_i="8571" txt_f="8573">1 </offsets></sub><offsets xml_i="13011" xml_f="13020" txt_i="8573" txt_f="8582">and of PD</offsets><sub><offsets xml_i="13025" xml_f="13028" txt_i="8582" txt_f="8585">20 </offsets></sub><offsets xml_i="13034" xml_f="13078" txt_i="8585" txt_f="8629">were made using paired Student's t-tests. PD</offsets><sub><offsets xml_i="13083" xml_f="13086" txt_i="8629" txt_f="8632">20 </offsets></sub><offsets xml_i="13092" xml_f="13133" txt_i="8632" txt_f="8673">values were log-transformed for analysis.</offsets></p><p><offsets xml_i="13140" xml_f="13260" txt_i="8674" txt_f="8794">Previous studies indicated that a sample size of 12 subjects would detect a 30% fall in AUC with 80% power at α = 0.05 [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="13291" xml_f="13292" txt_i="8794" txt_f="8795">5</offsets></xref><offsets xml_i="13299" xml_f="13301" txt_i="8795" txt_f="8797">].</offsets></p></sec></sec><sec><title><offsets xml_i="13329" xml_f="13336" txt_i="8800" txt_f="8807">Results</offsets></title><sec><title><offsets xml_i="13356" xml_f="13385" txt_i="8808" txt_f="8837">Study 1: High dose salbutamol</offsets></title><p><offsets xml_i="13396" xml_f="13512" txt_i="8838" txt_f="8954">Eleven subjects were recruited and completed the study. Baseline characteristics of the subjects are shown in table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="13544" xml_f="13545" txt_i="8954" txt_f="8955">1</offsets></xref><offsets xml_i="13552" xml_f="13633" txt_i="8955" txt_f="9036">. There was no significant effect of order of treatment on AUC, pre-challenge FEV</offsets><sub><offsets xml_i="13638" xml_f="13640" txt_i="9036" txt_f="9038">1 </offsets></sub><offsets xml_i="13646" xml_f="13651" txt_i="9038" txt_f="9043">or PD</offsets><sub><offsets xml_i="13656" xml_f="13659" txt_i="9043" txt_f="9046">20 </offsets></sub><offsets xml_i="13665" xml_f="13700" txt_i="9046" txt_f="9081">methacholine. The pre-challenge FEV</offsets><sub><offsets xml_i="13705" xml_f="13707" txt_i="9081" txt_f="9083">1 </offsets></sub><offsets xml_i="13713" xml_f="13719" txt_i="9083" txt_f="9089">and PD</offsets><sub><offsets xml_i="13724" xml_f="13727" txt_i="9089" txt_f="9092">20 </offsets></sub><offsets xml_i="13733" xml_f="13822" txt_i="9092" txt_f="9181">methacholine were not significantly different between placebo and formoterol arms (table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="13854" xml_f="13855" txt_i="9181" txt_f="9182">2</offsets></xref><offsets xml_i="13862" xml_f="13864" txt_i="9182" txt_f="9184">).</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="13912" xml_f="13919" txt_i="9185" txt_f="9192">Table 1</offsets></label><caption><p><offsets xml_i="13939" xml_f="13975" txt_i="9192" txt_f="9228">Baseline characteristics of subjects</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="14054" xml_f="14059" txt_i="9229" txt_f="9234">Study</offsets></td><td align="left"><offsets xml_i="14081" xml_f="14104" txt_i="9235" txt_f="9258">1. High dose salbutamol</offsets></td><td align="left"><offsets xml_i="14126" xml_f="14140" txt_i="9259" txt_f="9273">2. Ipratropium</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="14186" xml_f="14204" txt_i="9274" txt_f="9292">Number of subjects</offsets></td><td align="left"><offsets xml_i="14226" xml_f="14228" txt_i="9293" txt_f="9295">11</offsets></td><td align="left"><offsets xml_i="14250" xml_f="14252" txt_i="9296" txt_f="9298">11</offsets></td></tr><tr><td align="left"><offsets xml_i="14283" xml_f="14287" txt_i="9299" txt_f="9303">Male</offsets></td><td align="left"><offsets xml_i="14309" xml_f="14310" txt_i="9304" txt_f="9305">3</offsets></td><td align="left"><offsets xml_i="14332" xml_f="14333" txt_i="9306" txt_f="9307">3</offsets></td></tr><tr><td align="left"><offsets xml_i="14364" xml_f="14375" txt_i="9308" txt_f="9319">Age (range)</offsets></td><td align="left"><offsets xml_i="14397" xml_f="14410" txt_i="9320" txt_f="9333">37 (22 to 62)</offsets></td><td align="left"><offsets xml_i="14432" xml_f="14445" txt_i="9334" txt_f="9347">34 (19 to 53)</offsets></td></tr><tr><td align="left"><offsets xml_i="14476" xml_f="14541" txt_i="9348" txt_f="9413">Number on inhaled steroids Dose range (μg)(budesonide equivalent)</offsets></td><td align="left"><offsets xml_i="14563" xml_f="14578" txt_i="9414" txt_f="9429">9 (200 to 1200)</offsets></td><td align="left"><offsets xml_i="14600" xml_f="14616" txt_i="9430" txt_f="9446">10 (200 to 2000)</offsets></td></tr><tr><td align="left"><offsets xml_i="14647" xml_f="14650" txt_i="9447" txt_f="9450">FEV</offsets><sub><offsets xml_i="14655" xml_f="14656" txt_i="9450" txt_f="9451">1</offsets></sub><offsets xml_i="14662" xml_f="14694" txt_i="9451" txt_f="9483">% predicted at screening (range)</offsets></td><td align="left"><offsets xml_i="14716" xml_f="14730" txt_i="9484" txt_f="9498">79 (61 to 101)</offsets></td><td align="left"><offsets xml_i="14752" xml_f="14766" txt_i="9499" txt_f="9513">86 (65 to 103)</offsets></td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label><offsets xml_i="14849" xml_f="14856" txt_i="9514" txt_f="9521">Table 2</offsets></label><caption><p><offsets xml_i="14876" xml_f="14927" txt_i="9521" txt_f="9572">Results of the high dose salbutamol study (study 1)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="15006" xml_f="15015" txt_i="9573" txt_f="9582">Treatment</offsets></td><td align="center"><offsets xml_i="15039" xml_f="15046" txt_i="9583" txt_f="9590">Placebo</offsets></td><td align="center"><offsets xml_i="15070" xml_f="15080" txt_i="9591" txt_f="9601">Formoterol</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="15126" xml_f="15143" txt_i="9602" txt_f="9619">Pre-challenge FEV</offsets><sub><offsets xml_i="15148" xml_f="15150" txt_i="9619" txt_f="9621">1 </offsets></sub><offsets xml_i="15156" xml_f="15164" txt_i="9621" txt_f="9629">(L) (SD)</offsets></td><td align="center"><offsets xml_i="15188" xml_f="15199" txt_i="9630" txt_f="9641">2.55 (0.75)</offsets></td><td align="center"><offsets xml_i="15223" xml_f="15234" txt_i="9642" txt_f="9653">2.57 (0.72)</offsets></td></tr><tr><td align="left"><offsets xml_i="15265" xml_f="15283" txt_i="9654" txt_f="9672">Post challenge FEV</offsets><sub><offsets xml_i="15288" xml_f="15290" txt_i="9672" txt_f="9674">1 </offsets></sub><offsets xml_i="15296" xml_f="15304" txt_i="9674" txt_f="9682">(L) (SD)</offsets></td><td align="center"><offsets xml_i="15328" xml_f="15339" txt_i="9683" txt_f="9694">1.92 (0.59)</offsets></td><td align="center"><offsets xml_i="15363" xml_f="15374" txt_i="9695" txt_f="9706">2.00 (0.51)</offsets></td></tr><tr><td align="left"><offsets xml_i="15405" xml_f="15407" txt_i="9707" txt_f="9709">PD</offsets><sub><offsets xml_i="15412" xml_f="15415" txt_i="9709" txt_f="9712">20 </offsets></sub><offsets xml_i="15421" xml_f="15463" txt_i="9712" txt_f="9754">methacholine (mg) (geometric mean, 95% CI)</offsets></td><td align="center"><offsets xml_i="15487" xml_f="15504" txt_i="9755" txt_f="9772">0.08 (0.03, 0.22)</offsets></td><td align="center"><offsets xml_i="15528" xml_f="15545" txt_i="9773" txt_f="9790">0.10 (0.04, 0.25)</offsets></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="15615" xml_f="15643" txt_i="9792" txt_f="9820">AUC salbutamol (%.time) (SD)</offsets></td><td align="center"><offsets xml_i="15667" xml_f="15676" txt_i="9821" txt_f="9830">412 (140)</offsets></td><td align="center"><offsets xml_i="15700" xml_f="15709" txt_i="9831" txt_f="9840">339 (201)</offsets></td></tr><tr><td align="left"><offsets xml_i="15740" xml_f="15774" txt_i="9841" txt_f="9875">Difference: paired t-test (95% CI)</offsets></td><td align="center" colspan="2"><offsets xml_i="15810" xml_f="15831" txt_i="9876" txt_f="9897">73 (-4, 149) p = 0.06</offsets></td></tr><tr><td align="left"><offsets xml_i="15862" xml_f="15943" txt_i="9898" txt_f="9979">Difference: covariate analysis (placebo-formoterol) (least squares means, 95% CI)</offsets></td><td align="center" colspan="2"><offsets xml_i="15979" xml_f="16001" txt_i="9980" txt_f="10002">63 (22, 105) p = 0.008</offsets></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="16071" xml_f="16090" txt_i="10004" txt_f="10023">Post-salbutamol FEV</offsets><sub><offsets xml_i="16095" xml_f="16097" txt_i="10023" txt_f="10025">1 </offsets></sub><offsets xml_i="16103" xml_f="16122" txt_i="10025" txt_f="10044">at 20 mins (L) (SD)</offsets></td><td align="center"><offsets xml_i="16146" xml_f="16157" txt_i="10045" txt_f="10056">2.79 (0.86)</offsets></td><td align="center"><offsets xml_i="16181" xml_f="16192" txt_i="10057" txt_f="10068">2.67 (0.84)</offsets></td></tr><tr><td align="left"><offsets xml_i="16223" xml_f="16257" txt_i="10069" txt_f="10103">Difference: paired t-test (95% CI)</offsets></td><td align="center" colspan="2"><offsets xml_i="16293" xml_f="16320" txt_i="10104" txt_f="10131">0.12 (0.03, 0.20) p = 0.008</offsets></td></tr><tr><td align="left"><offsets xml_i="16351" xml_f="16432" txt_i="10132" txt_f="10213">Difference: covariate analysis (placebo-formoterol) (least squares means, 95% CI)</offsets></td><td align="center" colspan="2"><offsets xml_i="16468" xml_f="16495" txt_i="10214" txt_f="10241">0.12 (0.06, 0.19) p = 0.003</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="16537" xml_f="16785" txt_i="10242" txt_f="10490">The salbutamol response, expressed as area under the curve, was 15% lower in the formoterol period compared to placebo (95% confidence interval 5 to 25%). This was a significant difference when taking the covariates into account (p = 0.008) (table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="16817" xml_f="16818" txt_i="10490" txt_f="10491">2</offsets></xref><offsets xml_i="16825" xml_f="16834" txt_i="10491" txt_f="10500">, figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="16864" xml_f="16865" txt_i="10500" txt_f="10501">1</offsets></xref><offsets xml_i="16872" xml_f="16874" txt_i="10501" txt_f="10503">).</offsets></p><fig position="float" id="F1"><label><offsets xml_i="16915" xml_f="16923" txt_i="10504" txt_f="10512">Figure 1</offsets></label><caption><p><offsets xml_i="16943" xml_f="16985" txt_i="10512" txt_f="10554">Response to high dose salbutamol (n = 11).</offsets></p></caption><graphic xlink:href="1465-9921-8-19-1"></graphic></fig><p><offsets xml_i="17057" xml_f="17070" txt_i="10555" txt_f="10568">The final FEV</offsets><sub><offsets xml_i="17075" xml_f="17077" txt_i="10568" txt_f="10570">1 </offsets></sub><offsets xml_i="17083" xml_f="17248" txt_i="10570" txt_f="10735">20 minutes after challenge after 5 mg salbutamol was 2.67 L in the formoterol arm compared to 2.79 L after placebo (95% CI for difference 0.06 to 0.19 L; p = 0.003).</offsets></p></sec><sec><title><offsets xml_i="17270" xml_f="17298" txt_i="10737" txt_f="10765">Study 2: Ipratropium bromide</offsets></title><p><offsets xml_i="17309" xml_f="17569" txt_i="10766" txt_f="11026">Thirteen subjects were recruited to the study. Two subjects withdrew during the first treatment period, one with uncontrolled asthma and one with a respiratory infection (taking formoterol and placebo respectively). Baseline characteristics are shown in table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="17601" xml_f="17602" txt_i="11026" txt_f="11027">1</offsets></xref><offsets xml_i="17609" xml_f="17653" txt_i="11027" txt_f="11071">. There was no effect of order of treatment.</offsets></p><p><offsets xml_i="17660" xml_f="17686" txt_i="11072" txt_f="11098">The mean pre-challenge FEV</offsets><sub><offsets xml_i="17691" xml_f="17693" txt_i="11098" txt_f="11100">1 </offsets></sub><offsets xml_i="17699" xml_f="17705" txt_i="11100" txt_f="11106">and PD</offsets><sub><offsets xml_i="17710" xml_f="17713" txt_i="11106" txt_f="11109">20 </offsets></sub><offsets xml_i="17719" xml_f="17852" txt_i="11109" txt_f="11242">saline did not change significantly between formoterol and placebo arms. However, one subject experienced a less than 15% fall in FEV</offsets><sub><offsets xml_i="17857" xml_f="17859" txt_i="11242" txt_f="11244">1 </offsets></sub><offsets xml_i="17865" xml_f="17947" txt_i="11244" txt_f="11326">with inhalation of saline after taking formoterol. For analytical purposes, the PD</offsets><sub><offsets xml_i="17952" xml_f="17955" txt_i="11326" txt_f="11329">20 </offsets></sub><offsets xml_i="17961" xml_f="18142" txt_i="11329" txt_f="11510">saline for these challenges has been assumed to be 30 ml (the maximum value available for inhalation). Exclusion of this subject from analysis does not materially alter the results.</offsets></p><p><offsets xml_i="18149" xml_f="18284" txt_i="11511" txt_f="11646">The response to ipratropium, expressed as the AUC, was not significantly different between formoterol or placebo treatment arms (table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="18316" xml_f="18317" txt_i="11646" txt_f="11647">3</offsets></xref><offsets xml_i="18324" xml_f="18333" txt_i="11647" txt_f="11656">, figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="18363" xml_f="18364" txt_i="11656" txt_f="11657">2</offsets></xref><offsets xml_i="18371" xml_f="18387" txt_i="11657" txt_f="11673">). The final FEV</offsets><sub><offsets xml_i="18392" xml_f="18393" txt_i="11673" txt_f="11674">1</offsets></sub><offsets xml_i="18399" xml_f="18501" txt_i="11674" txt_f="11776">, 30 minutes after ipratropium was not significantly different between the formoterol or placebo arms.</offsets></p><table-wrap position="float" id="T3"><label><offsets xml_i="18549" xml_f="18556" txt_i="11777" txt_f="11784">Table 3</offsets></label><caption><p><offsets xml_i="18576" xml_f="18618" txt_i="11784" txt_f="11826">Results of the ipratropium study (study 2)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="18697" xml_f="18711" txt_i="11827" txt_f="11841">Bronchodilator</offsets></td><td align="center" colspan="2"><offsets xml_i="18747" xml_f="18758" txt_i="11842" txt_f="11853">Ipratropium</offsets></td><td align="center" colspan="2"><offsets xml_i="18794" xml_f="18804" txt_i="11854" txt_f="11864">Salbutamol</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="18850" xml_f="18859" txt_i="11865" txt_f="11874">Treatment</offsets></td><td align="center"><offsets xml_i="18883" xml_f="18890" txt_i="11875" txt_f="11882">Placebo</offsets></td><td align="center"><offsets xml_i="18914" xml_f="18924" txt_i="11883" txt_f="11893">Formoterol</offsets></td><td align="center"><offsets xml_i="18948" xml_f="18955" txt_i="11894" txt_f="11901">Placebo</offsets></td><td align="center"><offsets xml_i="18979" xml_f="18989" txt_i="11902" txt_f="11912">Formoterol</offsets></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="19059" xml_f="19076" txt_i="11914" txt_f="11931">Pre-challenge FEV</offsets><sub><offsets xml_i="19081" xml_f="19083" txt_i="11931" txt_f="11933">1 </offsets></sub><offsets xml_i="19089" xml_f="19097" txt_i="11933" txt_f="11941">(L) (SD)</offsets></td><td align="center"><offsets xml_i="19121" xml_f="19132" txt_i="11942" txt_f="11953">2.77 (0.50)</offsets></td><td align="center"><offsets xml_i="19156" xml_f="19167" txt_i="11954" txt_f="11965">2.67 (0.41)</offsets></td><td align="center"><offsets xml_i="19191" xml_f="19202" txt_i="11966" txt_f="11977">2.62 (0.50)</offsets></td><td align="center"><offsets xml_i="19226" xml_f="19237" txt_i="11978" txt_f="11989">2.67 (0.63)</offsets></td></tr><tr><td align="left"><offsets xml_i="19268" xml_f="19286" txt_i="11990" txt_f="12008">Post-challenge FEV</offsets><sub><offsets xml_i="19291" xml_f="19292" txt_i="12008" txt_f="12009">1</offsets></sub><offsets xml_i="19298" xml_f="19305" txt_i="12009" txt_f="12016">(L)(SD)</offsets></td><td align="center"><offsets xml_i="19329" xml_f="19340" txt_i="12017" txt_f="12028">2.15 (0.38)</offsets></td><td align="center"><offsets xml_i="19364" xml_f="19375" txt_i="12029" txt_f="12040">2.07 (0.37)</offsets></td><td align="center"><offsets xml_i="19399" xml_f="19410" txt_i="12041" txt_f="12052">2.06 (0.41)</offsets></td><td align="center"><offsets xml_i="19434" xml_f="19445" txt_i="12053" txt_f="12064">2.11 (0.60)</offsets></td></tr><tr><td align="left"><offsets xml_i="19476" xml_f="19478" txt_i="12065" txt_f="12067">PD</offsets><sub><offsets xml_i="19483" xml_f="19486" txt_i="12067" txt_f="12070">20 </offsets></sub><offsets xml_i="19492" xml_f="19512" txt_i="12070" txt_f="12090">saline (ml) (95% CI)</offsets></td><td align="center"><offsets xml_i="19536" xml_f="19549" txt_i="12091" txt_f="12104">11.8 (7.4–19)</offsets></td><td align="center"><offsets xml_i="19573" xml_f="19587" txt_i="12105" txt_f="12119">8.0 (4.6–13.8)</offsets></td><td align="center"><offsets xml_i="19611" xml_f="19625" txt_i="12120" txt_f="12134">8.9 (4.9–16.0)</offsets></td><td align="center"><offsets xml_i="19649" xml_f="19663" txt_i="12135" txt_f="12149">8.6 (5.0–14.6)</offsets></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="19733" xml_f="19748" txt_i="12151" txt_f="12166">AUC %.time (SD)</offsets></td><td align="center"><offsets xml_i="19772" xml_f="19781" txt_i="12167" txt_f="12176">447 (215)</offsets></td><td align="center"><offsets xml_i="19805" xml_f="19814" txt_i="12177" txt_f="12186">401 (154)</offsets></td><td align="center"><offsets xml_i="19838" xml_f="19847" txt_i="12187" txt_f="12196">759 (203)</offsets></td><td align="center"><offsets xml_i="19871" xml_f="19880" txt_i="12197" txt_f="12206">557 (131)</offsets></td></tr><tr><td align="left"><offsets xml_i="19911" xml_f="19945" txt_i="12207" txt_f="12241">Difference: paired t-test (95% CI)</offsets></td><td align="center" colspan="2"><offsets xml_i="19981" xml_f="20004" txt_i="12242" txt_f="12265">138 (-48,138) p = 0.303</offsets></td><td align="center" colspan="2"><offsets xml_i="20040" xml_f="20063" txt_i="12266" txt_f="12289">202 (66, 339) p = 0.008</offsets></td></tr><tr><td align="left"><offsets xml_i="20094" xml_f="20174" txt_i="12290" txt_f="12370">Difference: covariate analysis (placebo-formoterol) (least squares mean, 95% CI)</offsets></td><td align="center" colspan="2"><offsets xml_i="20210" xml_f="20233" txt_i="12371" txt_f="12394">88 (-31, 207) p = 0.126</offsets></td><td align="center" colspan="2"><offsets xml_i="20269" xml_f="20292" txt_i="12395" txt_f="12418">202 (42, 362) p = 0.019</offsets></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="20362" xml_f="20365" txt_i="12420" txt_f="12423">FEV</offsets><sub><offsets xml_i="20370" xml_f="20372" txt_i="12423" txt_f="12425">1 </offsets></sub><offsets xml_i="20378" xml_f="20397" txt_i="12425" txt_f="12444">at 30 mins (L) (SD)</offsets></td><td align="center"><offsets xml_i="20421" xml_f="20432" txt_i="12445" txt_f="12456">2.81 (0.54)</offsets></td><td align="center"><offsets xml_i="20456" xml_f="20467" txt_i="12457" txt_f="12468">2.67 (0.45)</offsets></td><td align="center"><offsets xml_i="20491" xml_f="20502" txt_i="12469" txt_f="12480">2.91 (0.56)</offsets></td><td align="center"><offsets xml_i="20526" xml_f="20537" txt_i="12481" txt_f="12492">2.74 (0.64)</offsets></td></tr><tr><td align="left"><offsets xml_i="20568" xml_f="20602" txt_i="12493" txt_f="12527">Difference: paired t-test (95% CI)</offsets></td><td align="center" colspan="2"><offsets xml_i="20638" xml_f="20661" txt_i="12528" txt_f="12551">0.22 (0–0.30) p = 0.056</offsets></td><td align="center" colspan="2"><offsets xml_i="20697" xml_f="20725" txt_i="12552" txt_f="12580">0.10 (-0.05, 0.39) p = 0.117</offsets></td></tr><tr><td align="left"><offsets xml_i="20756" xml_f="20836" txt_i="12581" txt_f="12661">Difference: covariate analysis (placebo-formoterol) (least squares mean, 95% CI)</offsets></td><td align="center" colspan="2"><offsets xml_i="20872" xml_f="20900" txt_i="12662" txt_f="12690">0.11 (-0.06, 0.28) p = 0.172</offsets></td><td align="center" colspan="2"><offsets xml_i="20936" xml_f="20963" txt_i="12691" txt_f="12718">0.22 (0.05, 0.38) p = 0.015</offsets></td></tr></tbody></table></table-wrap><fig position="float" id="F2"><label><offsets xml_i="21039" xml_f="21047" txt_i="12719" txt_f="12727">Figure 2</offsets></label><caption><p><offsets xml_i="21067" xml_f="21123" txt_i="12727" txt_f="12783">Response to salbutamol and ipratropium bromide (n = 11).</offsets></p></caption><graphic xlink:href="1465-9921-8-19-2"></graphic></fig><p><offsets xml_i="21195" xml_f="21351" txt_i="12784" txt_f="12940">The response to salbutamol was reduced in the formoterol arm compared to placebo. The mean difference in the AUC was 26% (95% CI 6 to 46%; p = 0.02) (table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="21383" xml_f="21384" txt_i="12940" txt_f="12941">3</offsets></xref><offsets xml_i="21391" xml_f="21400" txt_i="12941" txt_f="12950">, figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="21430" xml_f="21431" txt_i="12950" txt_f="12951">2</offsets></xref><offsets xml_i="21438" xml_f="21448" txt_i="12951" txt_f="12961">). The FEV</offsets><sub><offsets xml_i="21453" xml_f="21455" txt_i="12961" txt_f="12963">1 </offsets></sub><offsets xml_i="21461" xml_f="21642" txt_i="12963" txt_f="13144">30 minutes after salbutamol was also lower in the formoterol arm compared to placebo, 2.74 L compared to 2.91 L (95% CI for difference 0.05 to 0.38; p = 0.02 by covariate analysis).</offsets></p></sec></sec><sec><title><offsets xml_i="21670" xml_f="21680" txt_i="13147" txt_f="13157">Discussion</offsets></title><p><offsets xml_i="21691" xml_f="21992" txt_i="13158" txt_f="13459">These studies confirm that the response to salbutamol is reduced in subjects taking long-acting beta-agonists. This reduction in response was evident even when 5 mg salbutamol was given via nebuliser. By contrast, the bronchodilator response to ipratropium was not affected by prior use of formoterol.</offsets></p><p><offsets xml_i="21999" xml_f="22327" txt_i="13460" txt_f="13788">It is known that tolerance to bronchodilation occurs following regular formoterol. This has usually been demonstrated by measuring the bronchodilator response to up to 400 μg of salbutamol via metered dose inhaler. In terms of bronchodilation, 2.5 mg via a nebuliser is equivalent to 800 μg via metered dose inhaler and spacer [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="22359" xml_f="22361" txt_i="13788" txt_f="13790">22</offsets></xref><offsets xml_i="22368" xml_f="22562" txt_i="13790" txt_f="13984">]. We used a 5 mg dose of nebulised salbutamol in this study as this is commonly used in the emergency treatment of asthma. Higher single doses of salbutamol in a nebuliser are not recommended [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="22593" xml_f="22594" txt_i="13984" txt_f="13985">2</offsets></xref><offsets xml_i="22601" xml_f="22960" txt_i="13985" txt_f="14344">]. We found that the response to 5 mg of salbutamol was impaired after 1 week of regular formoterol use, indicating that patients using long-acting beta-agonists are likely to respond poorly to first-line treatment of acute severe asthma even if high doses of nebulised beta-agonist are used. Although the differences in the dose-response curves and final FEV</offsets><sub><offsets xml_i="22965" xml_f="22967" txt_i="14344" txt_f="14346">1 </offsets></sub><offsets xml_i="22973" xml_f="23122" txt_i="14346" txt_f="14495">shown in this study may appear modest, it has been shown that the degree of beta-agonist tolerance increases with the degree of bronchoconstriction [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="23153" xml_f="23154" txt_i="14495" txt_f="14496">7</offsets></xref><offsets xml_i="23161" xml_f="23269" txt_i="14496" txt_f="14604">]. Patients with acute severe asthma will have much more severe bronchoconstriction than the 20% fall in FEV</offsets><sub><offsets xml_i="23274" xml_f="23276" txt_i="14604" txt_f="14606">1 </offsets></sub><offsets xml_i="23282" xml_f="23305" txt_i="14606" txt_f="14629">induced in this study [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="23336" xml_f="23337" txt_i="14629" txt_f="14630">2</offsets></xref><offsets xml_i="23344" xml_f="23345" txt_i="14630" txt_f="14631">,</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="23377" xml_f="23379" txt_i="14631" txt_f="14633">23</offsets></xref><offsets xml_i="23386" xml_f="23820" txt_i="14633" txt_f="15067">]. They are therefore likely to have a much greater impairment in response to beta-agonists. In practice, many patients are given repeated doses of beta-agonists via nebuliser during an acute exacerbation. It was not possible to test the effects of repeated nebulisations using this model owing to the time taken for nebulisation (around 5 minutes) and the effect of spontaneous recovery from methacholine-induced bronchoconstriction.</offsets></p><p><offsets xml_i="23827" xml_f="24080" txt_i="15068" txt_f="15321">The findings of the salbutamol study appear to contrast with those of a study which found no difference in the response to emergency department beta-agonist treatment between patients who had been taking long-acting beta-agonists and those who had not [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="24112" xml_f="24114" txt_i="15321" txt_f="15323">24</offsets></xref><offsets xml_i="24121" xml_f="24322" txt_i="15323" txt_f="15524">]. However, this emergency department study did not assess the preceding use of short-acting beta-agonists. Since almost all asthmatics take large doses of beta-agonists before presenting to hospital [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="24354" xml_f="24356" txt_i="15524" txt_f="15526">25</offsets></xref><offsets xml_i="24363" xml_f="24414" txt_i="15526" txt_f="15577">] and tolerance to beta-agonists develops rapidly [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="24446" xml_f="24448" txt_i="15577" txt_f="15579">11</offsets></xref><offsets xml_i="24455" xml_f="24532" txt_i="15579" txt_f="15656">], it is highly likely that the 'control' group had also developed tolerance.</offsets></p><p><offsets xml_i="24539" xml_f="25066" txt_i="15657" txt_f="16184">The bronchodilator response to ipratropium bromide was not impaired by prior use of long-acting beta-agonist. This confirms that the effect that we have interpreted as beta-agonist tolerance is specific to beta-agonists and unlikely to be due to a non-specific change in airway smooth muscle responsiveness. The intracellular effects of both beta-agonists and cholinergic agents are now known to be far more complex than action on single second messenger systems and there are plausible mechanisms of interaction between them [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="25098" xml_f="25100" txt_i="16184" txt_f="16186">16</offsets></xref><offsets xml_i="25107" xml_f="25108" txt_i="16186" txt_f="16187">,</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="25140" xml_f="25142" txt_i="16187" txt_f="16189">26</offsets></xref><offsets xml_i="25149" xml_f="25282" txt_i="16189" txt_f="16322">]. Muscarinic agonists appear to reduce the potency of beta-agonist bronchodilation, possibly through an effect on adenylyl cyclase [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="25314" xml_f="25316" txt_i="16322" txt_f="16324">17</offsets></xref><offsets xml_i="25323" xml_f="25407" txt_i="16324" txt_f="16408">]. The converse effect of muscarinic antagonists has been more difficult to assess [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="25439" xml_f="25441" txt_i="16408" txt_f="16410">27</offsets></xref><offsets xml_i="25448" xml_f="25894" txt_i="16410" txt_f="16856">]. Acetylcholine in human airways acts via muscarinic receptors to decrease cyclic AMP and reduce intracellular calcium release, thereby causing bronchoconstriction. Ipratropium blocks these actions, thereby reducing smooth muscle tone and causing bronchodilation. Cyclic AMP is also a key second-messenger in the response to beta-receptor activation. Regular exposure to beta-agonists appears to uncouple the beta-receptor from cAMP production [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="25926" xml_f="25928" txt_i="16856" txt_f="16858">28</offsets></xref><offsets xml_i="25935" xml_f="26212" txt_i="16858" txt_f="17135">]. Therefore it seemed possible that beta-agonist tolerance would also have an effect on the response to ipratropium. However, this was not discernible in our study. The addition of ipratropium bromide to beta-agonist treatment in acute severe asthma improves bronchodilation [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="26244" xml_f="26246" txt_i="17135" txt_f="17137">15</offsets></xref><offsets xml_i="26253" xml_f="26319" txt_i="17137" txt_f="17203">], whereas it affords little additional benefit in stable asthma [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="26351" xml_f="26353" txt_i="17203" txt_f="17205">29</offsets></xref><offsets xml_i="26360" xml_f="26814" txt_i="17205" txt_f="17659">]. It is possible that this is because the response to beta-agonist in severe asthma is impaired because of prior beta-agonist treatment, whereas the response to anticholinergic treatment is maintained. In this study the bronchodilator response to salbutamol was more rapid and greater than to ipratropium bromide, even after tolerance had developed. However, the effect of beta-agonist tolerance increases with increasing levels of bronchoconstriction [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="26845" xml_f="26846" txt_i="17659" txt_f="17660">7</offsets></xref><offsets xml_i="26853" xml_f="26942" txt_i="17660" txt_f="17749">]. In severe asthma the modest response to ipratropium bromide may become more important.</offsets></p><p><offsets xml_i="26949" xml_f="27093" txt_i="17750" txt_f="17894">These studies used formoterol as the long-acting beta-agonist. Studies in the emergency department have focussed on patients taking salmeterol [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="27125" xml_f="27127" txt_i="17894" txt_f="17896">24</offsets></xref><offsets xml_i="27134" xml_f="27562" txt_i="17896" txt_f="18324">]. Salmeterol is a partial agonist at the beta-receptor compared to formoterol and theoretically it may be less likely to induce tolerance. Alternatively, salmeterol could act as a partial antagonist to salbutamol and reduce the effects of salbutamol still further. In practice, trials that have compared bronchodilator tolerance using the challenge-rescue model have not found any difference between salmeterol and formoterol [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="27593" xml_f="27594" txt_i="18324" txt_f="18325">8</offsets></xref><offsets xml_i="27601" xml_f="27602" txt_i="18325" txt_f="18326">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="27634" xml_f="27636" txt_i="18326" txt_f="18328">10</offsets></xref><offsets xml_i="27643" xml_f="27645" txt_i="18328" txt_f="18330">].</offsets></p><p><offsets xml_i="27652" xml_f="27975" txt_i="18331" txt_f="18654">We have interpreted the reduction in response to beta-agonists as tolerance or tachyphylaxis to the effects of beta-agonists. Downregulation of the beta-receptors both in terms of receptor number and intracellular response to receptor stimulation is a pharmacologically predictable effect of repeated receptor stimulation [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="28007" xml_f="28009" txt_i="18654" txt_f="18656">28</offsets></xref><offsets xml_i="28016" xml_f="28405" txt_i="18656" txt_f="19045">]. An alternative explanation for the reduced response to beta-agonist is that some beta-receptors were still occupied by formoterol molecules at the time of the test and were therefore not available to bind to salbutamol, reducing its effect. We measured the bronchodilator response 36 hours after the last dose of formoterol. This is outside the normal duration of action of formoterol [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="28437" xml_f="28439" txt_i="19045" txt_f="19047">30</offsets></xref><offsets xml_i="28446" xml_f="28619" txt_i="19047" txt_f="19220">] and receptor occupancy should be minimal at this time. The 36-hour withdrawal of formoterol also minimises confounding of the results by large changes in pre-challenge FEV</offsets><sub><offsets xml_i="28624" xml_f="28626" txt_i="19220" txt_f="19222">1 </offsets></sub><offsets xml_i="28632" xml_f="28638" txt_i="19222" txt_f="19228">and PD</offsets><sub><offsets xml_i="28643" xml_f="28645" txt_i="19228" txt_f="19230">20</offsets></sub><offsets xml_i="28651" xml_f="28792" txt_i="19230" txt_f="19371">. Although one subject showed a bronchoprotective effect at this time, overall there were no significant differences in the pre-challenge FEV</offsets><sub><offsets xml_i="28797" xml_f="28799" txt_i="19371" txt_f="19373">1 </offsets></sub><offsets xml_i="28805" xml_f="28810" txt_i="19373" txt_f="19378">or PD</offsets><sub><offsets xml_i="28815" xml_f="28818" txt_i="19378" txt_f="19381">20 </offsets></sub><offsets xml_i="28824" xml_f="28920" txt_i="19381" txt_f="19477">values. However, it is also known that beta-receptors recover rapidly following downregulation [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="28952" xml_f="28954" txt_i="19477" txt_f="19479">31</offsets></xref><offsets xml_i="28961" xml_f="29218" txt_i="19479" txt_f="19736">] and the timing of challenges 36 hours after the last dose of long-acting beta-agonist may mean that the tolerance measured in these trials was actually lower than that experienced by patients who continue take their long-acting beta-agonists twice daily [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="29250" xml_f="29252" txt_i="19736" txt_f="19738">12</offsets></xref><offsets xml_i="29259" xml_f="29261" txt_i="19738" txt_f="19740">].</offsets></p><p><offsets xml_i="29268" xml_f="29862" txt_i="19741" txt_f="20335">There are potential limitations to our study design. First, this challenge-rescue model does not accurately reflect all of the pathophysiology of acute asthma, where airway inflammation, oedema and mucus production play important roles in airway obstruction. Nevertheless, airway smooth muscle contraction is important and is the main target of emergency bronchodilator treatment. In addition, not all of the subjects in these studies were taking inhaled corticosteroids, whereas current guidelines recommend that long-acting beta-agonists are used in conjunction with inhaled corticosteroids [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="29893" xml_f="29894" txt_i="20335" txt_f="20336">1</offsets></xref><offsets xml_i="29901" xml_f="29902" txt_i="20336" txt_f="20337">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="29933" xml_f="29934" txt_i="20337" txt_f="20338">2</offsets></xref><offsets xml_i="29941" xml_f="30040" txt_i="20338" txt_f="20437">]. There is conflicting evidence on whether systemic corticosteroids may partly reverse tolerance [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="30072" xml_f="30074" txt_i="20437" txt_f="20439">32</offsets></xref><offsets xml_i="30081" xml_f="30197" txt_i="20439" txt_f="20555">]. However, it is known that stable doses of inhaled corticosteroids do not influence the development of tolerance [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="30228" xml_f="30229" txt_i="20555" txt_f="20556">5</offsets></xref><offsets xml_i="30236" xml_f="30334" txt_i="20556" txt_f="20654">] and hence the use of inhaled corticosteroids was not a requirement in our selection of subjects.</offsets></p><p><offsets xml_i="30341" xml_f="30576" txt_i="20655" txt_f="20890">This study is the first to demonstrate that beta-agonist bronchodilator tolerance can be demonstrated using hypertonic saline. Most previous studies using the 'challenge-rescue' technique have used methacholine as the challenge agent [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="30607" xml_f="30608" txt_i="20890" txt_f="20891">5</offsets></xref><offsets xml_i="30615" xml_f="30616" txt_i="20891" txt_f="20892">-</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="30647" xml_f="30648" txt_i="20892" txt_f="20893">8</offsets></xref><offsets xml_i="30655" xml_f="30656" txt_i="20893" txt_f="20894">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="30688" xml_f="30690" txt_i="20894" txt_f="20896">10</offsets></xref><offsets xml_i="30697" xml_f="30698" txt_i="20896" txt_f="20897">-</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="30730" xml_f="30732" txt_i="20897" txt_f="20899">12</offsets></xref><offsets xml_i="30739" xml_f="30740" txt_i="20899" txt_f="20900">,</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="30772" xml_f="30774" txt_i="20900" txt_f="20902">33</offsets></xref><xref ref-type="bibr" rid="B34"><offsets xml_i="30813" xml_f="30815" txt_i="20902" txt_f="20904">34</offsets></xref><offsets xml_i="30822" xml_f="30947" txt_i="20904" txt_f="21029">]. A suboptimal response to salbutamol after exercise challenge has also been found when patients use regular beta-agonists [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="30978" xml_f="30979" txt_i="21029" txt_f="21030">9</offsets></xref><offsets xml_i="30986" xml_f="30988" txt_i="21030" txt_f="21032">].</offsets></p></sec><sec><title><offsets xml_i="31010" xml_f="31020" txt_i="21034" txt_f="21044">Conclusion</offsets></title><p><offsets xml_i="31031" xml_f="31527" txt_i="21045" txt_f="21541">In summary, these studies confirm that beta-agonist bronchodilator tolerance develops during long-acting beta-agonist treatment. This is not overcome by 5 mg of nebulised salbutamol. The effect is specific to beta-agonists and does not affect the response to ipratropium bromide. Patients using long-acting beta-agonists may respond less well to emergency beta-agonist treatment. Additional treatment with an alternative bronchodilator should be considered early in the course of an exacerbation.</offsets></p></sec><sec><title><offsets xml_i="31549" xml_f="31562" txt_i="21543" txt_f="21556">Abbreviations</offsets></title><p><offsets xml_i="31573" xml_f="31604" txt_i="21557" txt_f="21588">AMP – adenosine 5'monophosphate</offsets></p><p><offsets xml_i="31611" xml_f="31637" txt_i="21589" txt_f="21615">AUC – area under the curve</offsets></p><p><offsets xml_i="31644" xml_f="31647" txt_i="21616" txt_f="21619">FEV</offsets><sub><offsets xml_i="31652" xml_f="31654" txt_i="21619" txt_f="21621">1 </offsets></sub><offsets xml_i="31660" xml_f="31700" txt_i="21621" txt_f="21661">– forced expiratory volume in one second</offsets></p><p><offsets xml_i="31707" xml_f="31709" txt_i="21662" txt_f="21664">PD</offsets><sub><offsets xml_i="31714" xml_f="31717" txt_i="21664" txt_f="21667">20 </offsets></sub><offsets xml_i="31723" xml_f="31803" txt_i="21667" txt_f="21747">– dose of bronchoprovocational challenge agent required to produce a fall in FEV</offsets><sub><offsets xml_i="31808" xml_f="31810" txt_i="21747" txt_f="21749">1 </offsets></sub><offsets xml_i="31816" xml_f="31836" txt_i="21749" txt_f="21769">of 20% from baseline</offsets></p></sec><sec><title><offsets xml_i="31858" xml_f="31877" txt_i="21771" txt_f="21790">Competing interests</offsets></title><p><offsets xml_i="31888" xml_f="31948" txt_i="21791" txt_f="21851">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="31970" xml_f="31992" txt_i="21853" txt_f="21875">Authors' contributions</offsets></title><p><offsets xml_i="32003" xml_f="32242" txt_i="21876" txt_f="22115">SH contributed to the trial design, acquired the data, performed the statistical analysis and helped to draft the manuscript. RH conceived the study, participated in its design, interpretation of results and helped to draft the manuscript.</offsets></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We would like to thank the study participants. We also thank Dr J McLachlan and the staff of the Waikato Hospital Respiratory Laboratory, Dr Graham Mills and the Waikato Respiratory Research Unit and Jan Cowan of the Respiratory Research Unit in the Dunedin School of Medicine. The study was funded by the Waikato Respiratory Research Fund.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="book"><person-group person-group-type="editor"><name><surname>Institute NIHNHLB</surname></name></person-group><source>Global strategy for asthma management and prevention</source><year>2002</year><publisher-name>Bethesda </publisher-name><fpage>NIH publication no 96</fpage><lpage>3659A</lpage><comment>updated 2005</comment></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><collab>BTS</collab></person-group><article-title>British guideline on the management of asthma</article-title><source>Thorax</source><year>2003</year><volume>58</volume><issue>suppl 1</issue><fpage>1</fpage><lpage>83</lpage></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newnham</surname><given-names>DM</given-names></name><name><surname>Grove</surname><given-names>A</given-names></name><name><surname>McDevitt</surname><given-names>DG</given-names></name><name><surname>Lipworth</surname><given-names>BJ</given-names></name></person-group><article-title>Subsensitivity of bronchodilator and systemic β2 adrenergic responses after regular twice daily treatment with eformeterol dry powder in asthmatic patients</article-title><source>Thorax</source><year>1995</year><volume>50</volume><fpage>497</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">7597661</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>D</given-names></name><name><surname>Timmers</surname><given-names>MC</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>GBel</surname><given-names>EH</given-names></name><name><surname>Dijkman</surname><given-names>JH</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name></person-group><article-title>Long-term effects of a long-acting β2-adrenocepter agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma</article-title><source>N Engl J Med</source><year>1992</year><volume>327</volume><fpage>1198</fpage><lpage>1203</lpage><pub-id pub-id-type="pmid">1357550</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hancox</surname><given-names>RJ</given-names></name><name><surname>Aldridge</surname><given-names>RE</given-names></name><name><surname>Cowan</surname><given-names>JO</given-names></name><name><surname>Flannery</surname><given-names>EM</given-names></name><name><surname>Herbison</surname><given-names>GP</given-names></name><name><surname>McLachlan</surname><given-names>CR</given-names></name><name><surname>Town</surname><given-names>GI</given-names></name><name><surname>Taylor</surname><given-names>DR</given-names></name></person-group><article-title>Tolerance to beta agonists during acute bronchoconstriction</article-title><source>Eur Respir J</source><year>1999</year><volume>14</volume><fpage>283</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">10515402</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-3003.1999.14b08.x</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SL</given-names></name><name><surname>Cowan</surname><given-names>JO</given-names></name><name><surname>Flannery</surname><given-names>EM</given-names></name><name><surname>Hancox</surname><given-names>RJ</given-names></name><name><surname>Herbison</surname><given-names>GP</given-names></name><name><surname>Taylor</surname><given-names>DR</given-names></name></person-group><article-title>Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance</article-title><source>Eur Respir J</source><year>2001</year><volume>17</volume><fpage>368</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">11405513</pub-id><pub-id pub-id-type="doi">10.1183/09031936.01.17303680</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wraight</surname><given-names>JM</given-names></name><name><surname>Hancox</surname><given-names>RJ</given-names></name><name><surname>Herbison</surname><given-names>GP</given-names></name><name><surname>Cowan</surname><given-names>JO</given-names></name><name><surname>Flannery</surname><given-names>EM</given-names></name><name><surname>Taylor</surname><given-names>DR</given-names></name></person-group><article-title>Bronchodilator tolerance: the impact of increasing bronchoconstriction</article-title><source>Eur Respir J</source><year>2003</year><volume>21</volume><fpage>810</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">12765426</pub-id><pub-id pub-id-type="doi">10.1183/09031936.03.00067503</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van der Woude</surname><given-names>HJ</given-names></name><name><surname>Winter</surname><given-names>TH</given-names></name><name><surname>Aalbers</surname><given-names>R</given-names></name></person-group><article-title>Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting β2 agonists</article-title><source>Thorax</source><year>2001</year><volume>56</volume><fpage>529</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">11413351</pub-id><pub-id pub-id-type="doi">10.1136/thorax.56.7.529</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storms</surname><given-names>WW</given-names></name><name><surname>Chervinsky</surname><given-names>P</given-names></name><name><surname>Ghannam</surname><given-names>A</given-names></name><name><surname>Bird</surname><given-names>S</given-names></name><name><surname>Hustad</surname><given-names>CM</given-names></name><name><surname>Edelman</surname><given-names>JM</given-names></name></person-group><article-title>A comparison of the effects of oral montelukast and inhaled salmeterol on response to resuce bronchodilation after challenge</article-title><source>Respir Med</source><year>2004</year><volume>98</volume><fpage>1051</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">15526805</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2004.05.008</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DKC</given-names></name><name><surname>Jackson</surname><given-names>CM</given-names></name><name><surname>Currie</surname><given-names>GP</given-names></name><name><surname>Cockburn</surname><given-names>WJ</given-names></name><name><surname>Lipworth</surname><given-names>BJ</given-names></name></person-group><article-title>Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma</article-title><source>Br J Clin Pharmacol</source><year>2003</year><volume>56</volume><fpage>494</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">14651722</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.01887.x</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haney</surname><given-names>S</given-names></name><name><surname>Hancox</surname><given-names>RJ</given-names></name></person-group><article-title>Rapid onset of tolerance to beta-agonist bronchodilation</article-title><source>Respir Med</source><year>2005</year><volume>99</volume><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">15823453</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2004.10.014</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haney</surname><given-names>S</given-names></name><name><surname>Hancox</surname><given-names>RJ</given-names></name></person-group><article-title>Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial</article-title><source>Respiratory Research</source><year>2005</year><volume>6</volume><fpage>107</fpage><pub-id pub-id-type="pmid">16168062</pub-id><pub-id pub-id-type="doi">10.1186/1465-9921-6-107</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haney</surname><given-names>S</given-names></name><name><surname>Hancox</surname><given-names>RJ</given-names></name></person-group><article-title>Recovery from bronchoconstriction and bronchodilator tolerance</article-title><source>Clin Rev Allergy Immunol</source><year>2006</year><volume>31</volume><fpage>181</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">17085792</pub-id><pub-id pub-id-type="doi">10.1385/CRIAI:31:2:181</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sears</surname><given-names>MR</given-names></name><name><surname>Lotvall</surname><given-names>J</given-names></name></person-group><article-title>Past, present and future - β2-adrenoceptor agonists in asthma management</article-title><source>Respir Med</source><year>2005</year><volume>99</volume><fpage>152</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">15715182</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2004.07.003</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodrigo</surname><given-names>G</given-names></name><name><surname>Rodrigo</surname><given-names>C</given-names></name></person-group><article-title>The role of anticholinergics in acute asthma treatment</article-title><source>Chest</source><year>2002</year><volume>121</volume><fpage>1977</fpage><lpage>1987</lpage><pub-id pub-id-type="pmid">12065366</pub-id><pub-id pub-id-type="doi">10.1378/chest.121.6.1977</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giembycz</surname><given-names>MA</given-names></name><name><surname>Newton</surname><given-names>R</given-names></name></person-group><article-title>Beyond the dogma: novel β2-adrenoceptor signalling in the airways</article-title><source>Eur Respir J</source><year>2006</year><volume>27</volume><issue>6</issue><fpage>1286</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">16772391</pub-id><pub-id pub-id-type="doi">10.1183/09031936.06.00112605</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarria</surname><given-names>B</given-names></name><name><surname>Naline</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cortijo</surname><given-names>J</given-names></name><name><surname>Molimard</surname><given-names>M</given-names></name><name><surname>Moreau</surname><given-names>J</given-names></name><name><surname>Therond</surname><given-names>P</given-names></name><name><surname>Advernier</surname><given-names>C</given-names></name><name><surname>Morcillo</surname><given-names>EJ</given-names></name></person-group><article-title>Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus</article-title><source>American Journal of Lung Cell Molecular Physiology</source><year>2002</year><volume>283</volume><fpage>L1125</fpage><lpage>L1132</lpage></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>O'Byrne</surname><given-names>PM</given-names></name><name><surname>Swystun</surname><given-names>VA</given-names></name><name><surname>Bhagat</surname><given-names>R</given-names></name></person-group><article-title>Regular use of inhaled albuterol and the allergen-induced late asthmatic response</article-title><source>J Allergy Clin Immunol</source><year>1995</year><volume>96</volume><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">7622762</pub-id><pub-id pub-id-type="doi">10.1016/S0091-6749(95)70031-5</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hancox</surname><given-names>RJ</given-names></name><name><surname>Subbarao</surname><given-names>P</given-names></name><name><surname>Kamada</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>R</given-names></name><name><surname>Hargreave</surname><given-names>FE</given-names></name><name><surname>Inman</surname><given-names>MD</given-names></name></person-group><article-title>Beta 2 agonist tolerance and exercise-induced bronchospasm</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>165</volume><fpage>1068</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">11956046</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>K</given-names></name><name><surname>Salome</surname><given-names>C</given-names></name><name><surname>Woolcock</surname><given-names>AJ</given-names></name></person-group><article-title>Rapid method for measurement of bronchial responsiveness</article-title><source>Thorax</source><year>1983</year><volume>38</volume><fpage>760</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">6648855</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sterk</surname><given-names>PJ</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>O'Byrne</surname><given-names>PM</given-names></name><name><surname>Anderson</surname><given-names>SD</given-names></name><name><surname>Juniper</surname><given-names>EF</given-names></name><name><surname>Malo</surname><given-names>JL</given-names></name></person-group><article-title>Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults</article-title><source>Eur Respir J</source><year>1993</year><volume>6</volume><fpage>53</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">8425595</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colacone</surname><given-names>A</given-names></name><name><surname>Afilalo</surname><given-names>M</given-names></name><name><surname>Wolkove</surname><given-names>N</given-names></name><name><surname>Kreisman</surname><given-names>H</given-names></name></person-group><article-title>A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma</article-title><source>Chest</source><year>1993</year><volume>104</volume><fpage>835</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">8365298</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodrigo</surname><given-names>GJ</given-names></name><name><surname>Rodrigo</surname><given-names>C</given-names></name></person-group><article-title>First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>161</volume><issue>6</issue><fpage>1862</fpage><lpage>1868</lpage><pub-id pub-id-type="pmid">10852758</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korosec</surname><given-names>M</given-names></name><name><surname>Novak</surname><given-names>RD</given-names></name><name><surname>Myers</surname><given-names>E</given-names></name><name><surname>Skowronski</surname><given-names>M</given-names></name><name><surname>McFadden</surname><given-names>ER</given-names></name></person-group><article-title>Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma</article-title><source>Am J Med</source><year>1999</year><volume>107</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">10492312</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9343(99)00222-3</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Windom</surname><given-names>HH</given-names></name><name><surname>Burgess</surname><given-names>CD</given-names></name><name><surname>Crane</surname><given-names>J</given-names></name><name><surname>Pearce</surname><given-names>N</given-names></name><name><surname>Kwong</surname><given-names>T</given-names></name><name><surname>Beasley</surname><given-names>R</given-names></name></person-group><article-title>The self-administration of inhaled beta agonist drugs during severe asthma</article-title><source>N Z Med J</source><year>1990</year><volume>103</volume><fpage>205</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">2342689</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gosens</surname><given-names>R</given-names></name><name><surname>Zaagsma</surname><given-names>J</given-names></name><name><surname>Meurs</surname><given-names>H</given-names></name><name><surname>Halayko</surname><given-names>AJ</given-names></name></person-group><article-title>Muscarinic receptor signalling in the pathophysiology of asthma and COPD</article-title><source>Respiratory Research</source><year>2006</year><volume>7</volume><fpage>73</fpage><pub-id pub-id-type="pmid">16684353</pub-id><pub-id pub-id-type="doi">10.1186/1465-9921-7-73</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>N</given-names></name><name><surname>Magnussen</surname><given-names>H</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name></person-group><article-title>Antagonism of β-adrenoceptor-mediated relaxations of human bronchial smooth muscle by carbachol</article-title><source>Eur J Pharmacol</source><year>1995</year><volume>275</volume><fpage>307</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">7768300</pub-id><pub-id pub-id-type="doi">10.1016/0014-2999(95)00048-P</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Beta-adrenergic receptors and their regulation</article-title><source>Am J Respir Crit Care Med</source><year>1995</year><volume>152</volume><fpage>838</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">7663795</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ullah</surname><given-names>MI</given-names></name><name><surname>Newman</surname><given-names>GB</given-names></name><name><surname>Saunders</surname><given-names>KB</given-names></name></person-group><article-title>Influence of age on response to ipratropium and salbutamol in asthma</article-title><source>Thorax</source><year>1981</year><volume>36</volume><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">6458920</pub-id></citation></ref><ref id="B30"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Dollery</surname><given-names>C</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Dollery C</surname></name></person-group><article-title>Therapeutic Drugs: formoterol</article-title><source>Therapeutic Drugs</source><year>1999</year><edition>2</edition><publisher-name> Churchill Livingstone</publisher-name><fpage>F155</fpage><lpage>F158</lpage></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brodde</surname><given-names>OE</given-names></name><name><surname>Daul</surname><given-names>A</given-names></name><name><surname>Michel-Reher</surname><given-names>M</given-names></name><name><surname>Boosma</surname><given-names>F</given-names></name><name><surname>Man in't Veld</surname><given-names>AJ</given-names></name><name><surname>Schlieper</surname><given-names>P</given-names></name><name><surname>Michel</surname><given-names>MC</given-names></name></person-group><article-title>Agonist-induced desensitization of β-adrenoceptor function in humans</article-title><source>Circulation</source><year>1990</year><volume>81</volume><fpage>914</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">1968366</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hancox</surname><given-names>RJ</given-names></name></person-group><article-title>Interactions between corticosteroids and β2-agonists</article-title><source>Clin Rev Allergy Immunol</source><year>2006</year><volume>31</volume><fpage>231</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">17085796</pub-id><pub-id pub-id-type="doi">10.1385/CRIAI:31:2:231</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DKC</given-names></name><name><surname>Jackson</surname><given-names>CM</given-names></name><name><surname>Bates</surname><given-names>CE</given-names></name><name><surname>Lipworth</surname><given-names>BJ</given-names></name></person-group><article-title>Cross tolerance to salbutamol occurs independently of β2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol</article-title><source>Thorax</source><year>2004</year><volume>59</volume><fpage>662</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">15282385</pub-id><pub-id pub-id-type="doi">10.1136/thx.2003.019059</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makker</surname><given-names>HK</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name></person-group><article-title>Relation of the hypertonic saline responsiveness of the airways to exercise induced asthma symptom severity and to histamine or methacholine reactivity</article-title><source>Thorax</source><year>1993</year><volume>48</volume><fpage>142</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">8493628</pub-id></citation></ref></ref-list></back></article>